Cellares signed a long‑term lease for a Smart Factory facility at Leiden Bio Science Park to establish a European hub for automated cell‑therapy development and manufacturing. The ~105,000‑square‑foot site will house Cellares’ Cell Shuttle manufacturing platforms and Cell Q quality systems and is intended to support regional clinical and commercial supply. The company positioned the Netherlands site as part of a global IDMO network — complementing facilities in Bridgewater and South San Francisco — to enable consistent process transfer and reduced time‑to‑market for cell‑based programs. Phased fit‑out and initial occupancy are planned for 2026. Cellares emphasized the strategic importance of geographically distributed capacity for patient‑specific, time‑sensitive therapies and highlighted demand from European developers seeking automated, GMP‑aligned manufacturing. Source: company announcement.